Literature DB >> 23362950

Bile acids affect the growth of human cholangiocarcinoma via NF-kB pathway.

Jiaqi Dai1, Hongxia Wang, Ying Dong, Yinxin Zhang, Jian Wang.   

Abstract

We observed that free bile acids (CA, DCA, and CDCA) inhibited the growth of cholangiocarcinoma cells by promoting cell apoptosis, while the conjugated bile acids (GCA, GDCA, and GCDCA) stimulated cell growth. Consistently, we found that GDCA stimulated tumor growth and CDCA decreased tumor growth in xenografted mice. Further, the phosphorylated IkB was downregulated by free bile acids, and was upregulated by the conjugated bile acids. IL-6 and COX-2 were decreased by the free bile acids and increased by the conjugated bile acids. Collectively, these results suggest that the bile acids regulate the growth of cholangiocarcinoma by modulating NF-kB pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23362950     DOI: 10.3109/07357907.2012.762781

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  12 in total

1.  Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell Line.

Authors:  Runping Liu; Xiaojiaoyang Li; Xiaoyan Qiang; Lan Luo; Phillip B Hylemon; Zhenzhou Jiang; Luyong Zhang; Huiping Zhou
Journal:  J Biol Chem       Date:  2015-10-30       Impact factor: 5.157

2.  Taurolithocholic acid promotes intrahepatic cholangiocarcinoma cell growth via muscarinic acetylcholine receptor and EGFR/ERK1/2 signaling pathway.

Authors:  Sumet Amonyingcharoen; Tawit Suriyo; Apinya Thiantanawat; Piyajit Watcharasit; Jutamaad Satayavivad
Journal:  Int J Oncol       Date:  2015-03-27       Impact factor: 5.650

3.  The Major Role of NF-κB in the Depth of Invasion on Acral Melanoma by Decreasing CD8+ T Cells.

Authors:  Hermin Aminah Usman; Bethy S Hernowo; Maringan Diapari Lumban Tobing; Reti Hindritiani
Journal:  J Pathol Transl Med       Date:  2018-04-20

Review 4.  The role of tumour microenvironment: a new vision for cholangiocarcinoma.

Authors:  Ziyan Chen; Pengyi Guo; Xiaozai Xie; Haitao Yu; Yi Wang; Gang Chen
Journal:  J Cell Mol Med       Date:  2018-11-05       Impact factor: 5.310

Review 5.  Molecular Pathogenesis of Cholangiocarcinoma.

Authors:  Peter L Labib; George Goodchild; Stephen P Pereira
Journal:  BMC Cancer       Date:  2019-02-28       Impact factor: 4.430

6.  Importance of Bile Composition for Diagnosis of Biliary Obstructions.

Authors:  Łukasz Krupa; Robert Staroń; Dorota Dulko; Natalia Łozińska; Alan R Mackie; Neil M Rigby; Adam Macierzanka; Aleksandra Markiewicz; Christian Jungnickel
Journal:  Molecules       Date:  2021-11-30       Impact factor: 4.411

Review 7.  Research Progress of Bile Acids in Cancer.

Authors:  Junhao Fu; Min Yu; Wenxia Xu; Shian Yu
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

Review 8.  Biliary Diseases from the Microbiome Perspective: How Microorganisms Could Change the Approach to Benign and Malignant Diseases.

Authors:  Cecilia Binda; Giulia Gibiino; Chiara Coluccio; Monica Sbrancia; Elton Dajti; Emanuele Sinagra; Gabriele Capurso; Vittorio Sambri; Alessandro Cucchetti; Giorgio Ercolani; Carlo Fabbri
Journal:  Microorganisms       Date:  2022-01-28

9.  Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.

Authors:  Runping Liu; Renping Zhao; Xiqiao Zhou; Xiuyin Liang; Deanna J W Campbell; Xiaoxuan Zhang; Luyong Zhang; Ruihua Shi; Guangji Wang; William M Pandak; Alphonse E Sirica; Phillip B Hylemon; Huiping Zhou
Journal:  Hepatology       Date:  2014-07-28       Impact factor: 17.425

10.  FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression.

Authors:  Wei Wang; Ming Zhan; Qi Li; Wei Chen; Huiling Chu; Qihong Huang; Zhaoyuan Hou; Mohan Man; Jian Wang
Journal:  Oncotarget       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.